Rebys (HSP Gp96 vaccine) / Cure & Sure Biotech - LARVOL DELTA

Adjuvant gp96 immunotherapy plus SOX chemotherapy after gastrectomy: A randomized controlled trial (IGCC 2025) - "This trial is to investigate the safety and efficacy of autologous heat shock protein gp96 combined oxaliplatin plus S-1 (SOX) for gastric cancer patients in adjuvant settings... Postoperative adjuvant autologous gp96 immunotherapy with SOX chemotherapy shows survival benefit with acceptable adverse events."

Clinical • Gastric Cancer • Oncology • Solid Tumor

A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 (clinicaltrials.gov) - P2; N=150; Recruiting; Sponsor: Cure&Sure Biotech Co., LTD; Not yet recruiting ➔ Recruiting; Trial completion date: Aug 2023 ➔ Aug 2024

Enrollment open • Trial completion date